Skip to main content
. 2021 Feb 8;11:27. doi: 10.1186/s13613-021-00810-y

Fig. 2.

Fig. 2

All-cause mortality of the patients with eGFR ≥ 30 mL/min/1.73 m2 who received levosimendan versus dobutamine alone before (a) and after (b) propensity score matching